Royalty Pharma (RPRX) Accrued capitalized offering costs (2) — Quarterly & Annual

Screener

Discontinued — last reported Q3 '21

Accrued capitalized offering costs (2) at other companies

FCR

FutureCrest AcquisitionFCRS

$75K—

Republic Digital Acquisition CompanyRDAG

$75K—

XSL

XsollaXSLL

$75K—

HVI

Hennessy Capital Investment Corp. VIIHVII

$25K—

CUB

Lionheart HoldingsCUB

$75K—

KRAKacquisitionKRAQ

$20.57K—

Segments

By product

Trelegy$50M—

Other financials

Income statement

Revenue$674.1M+16.5%

Operating income$133.1M-36.5%

Net income$17.9M-44.4%

EPS (diluted)$0.04-42.9%

Balance sheet

Cash & equivalents$812.0M+28.5%

Total debt$9.0B+11.7%

Total equity$9.8B+3.1%

Total assets$19.8B+8.2%

Cash flow

Operating cash flow$728.5M+100%

Valuation

Market cap$25.6B+63.7%

Enterprise value$33.75B+46.5%

P/E31.4×+16.1×

P/S10.1×+3.3×

Profitability

Operating margin59.6%-20.2pp

Net margin32.1%-12.3pp

Returns & leverage

Return on equity8.5%-2.2pp

Debt / equity0.9×+0.1×

Current ratio2.8×+1.5×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept rprx:MilestonePaymentAccruedButNotPaid.

The source filing: Royalty Pharma’s 10-Q, filed November 10, 2021. Open the filing →

Filed: Nov 9, 2021, 7:00 PM EST
Fiscal quarter: Q3 FY2021
Calendar quarter: Q3 2021
Accession: 0001802768-21-000040

FAQ

What is Royalty Pharma's accrued capitalized offering costs (2)?: Royalty Pharma (RPRX) reported accrued capitalized offering costs (2) of $0 in Q3 2021.
What does accrued capitalized offering costs (2) mean?: Accrued capitalized offering costs (2) as reported by Royalty Pharma plc Class A Ordinary Shares.

Ask your AI about Royalty Pharma's accrued capitalized offering costs (2).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk